Pfizer Files Lawsuit to Halt Sales of Brenzys (biosimilar, etanercept) in Australia
Shots:
- Pfizer filed a new patent lawsuit against 5 companies (Samsung Bioepis, Merck, Sharp & Dohme, Organon, and Arrow) to stop the marketing of Brenzys, a biosimilar referencing etanercept in Australia. In the EU, Brenzys is marketed as Benepali
- Pfizer gets the marketing rights for Amgen’s etanercept. Pfizer asserts that the respondents' claims about cell culture methods infringe on Australian patent no. 2005280034 titled "Production of polypeptides"
- Pfizer & its subsidiary Hospira were prior involved in a patent dispute for biosimilars referencing Neupogen & Neulasta which are used to treat patients with FN who undergoes CT scan. Amgen & Pfizer have settled their agreement for filgrastim biosimilar in Sept 2021 & pegfilgrastim biosimilar for Mar 2021
Ref: The Center For Biosimilar | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
